Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Prostatype Genomics AB's Net-Net Working Capital for the quarter that ended in Dec. 2025 was kr-0.10.
The industry rank for Prostatype Genomics AB's Net-Net Working Capital or its related term are showing as below:
OSTO:PROGEN's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6.03 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Prostatype Genomics AB (OSTO:PROGEN) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Prostatype Genomics AB Net-Net Working Capital Related Terms
Prostatype Genomics AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Net-Net Working Capital Chart
OSTO:PROGEN vs TMO, DHR, IDXX: Net-Net Working Capital Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Price-to-Net-Net-Working-Capital vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of kr-0.10 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Net-Net Working Capital of kr-0.10 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Prostatype Genomics AB According to the industry distribution chart, Prostatype Genomics AB ranks #999999 out of 79 companies in the Medical Diagnostics & Research industry.
Is Prostatype Genomics AB's Net-Net Working Capital too high?
Prostatype Genomics AB's current Net-Net Working Capital is kr-0.10. Based on the distribution chart, Prostatype Genomics AB ranks #999999 out of 79 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Net-Net Working Capital compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #999999 out of 79 companies for Net-Net Working Capital. This places Prostatype Genomics AB in the lower half of its industry. The industry median Net-Net Working Capital is 6.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Diagnostics & Research company?
The median Net-Net Working Capital among Medical Diagnostics & Research companies is 6.03, based on 79 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Prostatype Genomics AB For the Medical Diagnostics & Research industry, the median Net-Net Working Capital is 6.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Net-Net Working Capital is kr-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.16 — trading 290% above its estimated fair value. The current Net-Net Working Capital is kr-0.10. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Net-Net Working Capital is kr-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 290% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Net-Net Working Capital: kr-0.10
GF Value™: kr0.04 vs. price of kr0.16 (290% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
